<SEC-DOCUMENT>0001193125-25-144871.txt : 20250624
<SEC-HEADER>0001193125-25-144871.hdr.sgml : 20250624
<ACCEPTANCE-DATETIME>20250623204202
ACCESSION NUMBER:		0001193125-25-144871
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250623
FILED AS OF DATE:		20250624
DATE AS OF CHANGE:		20250623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251066422

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d912008d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as June 23, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d912008dex991.htm">Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: June 23, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d912008dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g912008dsp5.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:4pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:4pt">
<TD VALIGN="top" BGCOLOR="#71b484">&#8194;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Positive Update from Phase I Study of IMP761, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT>
<FONT STYLE="white-space:nowrap">LAG-3</FONT> Agonist Antibody for Autoimmune Diseases </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell
suppression and a favourable safety profile at dosing level of 0.9 mg/kg </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune
diseases </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Single ascending dose levels will continue with 2.5, 7 and 14 mg/kg </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional data from the Phase I to follow in second half of CY2025 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; June</B><B></B><B>&nbsp;23, </B><B>2025 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase I study evaluating IMP761, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
<FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody for autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the highest dosing level to date (0.9 mg/kg of IMP761),
there have been no treatment-related adverse events in healthy participants. Additionally, pharmacodynamic data at this dosing level show that the inhibition of T cell infiltration in the skin at day 10 following a neoantigen rechallenge has already
reached 80%. Given the encouraging efficacy and safety, Immutep is continuing with single ascending dose levels of 2.5, 7 and 14 mg/kg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">LAG-3</FONT> (lymphocyte-activation <FONT STYLE="white-space:nowrap">gene-3)</FONT> immune checkpoint has been identified as a promising therapeutic target for rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis
in multiple publications.<SUP STYLE="font-size:75%; vertical-align:top">1-3</SUP>&nbsp;IMP761 is the first <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody developed to potentially treat these large and growing disorders, each of which
represent multi-billion dollar markets, and many other autoimmune diseases. By enhancing the &#147;brake&#148; function of <FONT STYLE="white-space:nowrap">LAG-3</FONT> to silence dysregulated self-antigen-specific memory T cells, IMP761 is designed
to target the cause of autoimmune diseases and restore balance to the immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of
Immutep, said:</B> &#147;The early pharmacological data showing substantial T cell suppression at the highest dose level of IMP761 are very promising, especially in conjunction with its continued favourable safety profile, and highlight the
potential efficacy of this <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist in treating autoimmune diseases. <FONT STYLE="white-space:nowrap">LAG-3</FONT> expression on activated T cells is known to be highly specific to disease sites, and
particularly in areas of chronic inflammation. This unique specificity enables the potential for IMP761 to have a more targeted approach with fewer side effects than other therapies. We look forward to evaluating higher dosing levels of IMP761 and
hope to further enhance its ability to safely silence the dysregulated T cells responsible for many autoimmune diseases.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase I trial is being
conducted by the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. In addition to the safety analysis, CHDR is implementing its keyhole limpet haemocyanin (KLH) challenge model to evaluate IMP761&#146;s pharmacological activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional data from the Phase I to follow in second half of CY2025. For more information on the trial, please visit clinicaltrials.gov (NCT06637865). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g912008dsp5.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:4pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:4pt">
<TD VALIGN="top" BGCOLOR="#71b484">&#8194;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761, a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive lymphocyte-activation <FONT STYLE="white-space:nowrap">gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3)</FONT> agonist antibody, has the
potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the immune system. As published in the <U>Journal of Immunology</U>,
encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT> in vivo and in vitro studies show IMP761 inhibits peptide-induced T cell proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH)
reaction.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> Additional preclinical data in oligoarticular juvenile idiopathic arthritis <FONT STYLE="white-space:nowrap">(o-JIA)</FONT> published in <U>Pediatric Research</U> details how IMP761 led
to a decrease in a broad spectrum of effector cytokines.<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> This study also shows children with <FONT STYLE="white-space:nowrap">o-JIA</FONT> have a skewed
<FONT STYLE="white-space:nowrap">LAG-3</FONT> metabolism and suggests they can benefit from agonistic <FONT STYLE="white-space:nowrap">LAG-3</FONT> activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a late-stage biotechnology
company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to
bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Pedersen, J.M., Hansen, A.S., Skej&oslash;, C. et al. Lymphocyte activation gene 3 is increased and affects
cytokine production in rheumatoid arthritis. Arthritis Res Ther 25, 97 (2023). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1186/s13075-023-03073-z</FONT></FONT> </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Jones BE, Maerz MD et al. Fewer <FONT STYLE="white-space:nowrap">LAG-3+</FONT> T Cells in
Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. J Immunol. 2022 Feb <FONT STYLE="white-space:nowrap">1;208(3):594-602.</FONT> doi: 10.4049/jimmunol.2100850. Epub 2022 Jan 12. PMID: 35022272; PMCID: PMC8820445. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Zhou X, Gu Y et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy
for autoimmune diseases. Inflamm Res. 2023 Jun;72(6):1215-1235. doi: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1007/s00011-023-01742-y.</FONT></FONT></FONT> Epub 2023 Jun 14. PMID:
37314518. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Mathieu Angin, Chrystelle Brignone, Fr&eacute;d&eacute;ric Triebel; A
<FONT STYLE="white-space:nowrap">LAG-3&#150;Specific</FONT> Agonist Antibody for the Treatment of T Cell&#150;Induced Autoimmune Diseases. J Immunol 15<SUB STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;February 2020; 204 (4):
810&#150;818. https://doi.org/10.4049/jimmunol.1900823 </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Sag, E., Demir, S., Aspari, M. et al. Juvenile idiopathic arthritis: lymphocyte activation <FONT
STYLE="white-space:nowrap">gene-3</FONT> is a central immune receptor in children with oligoarticular subtypes. Pediatr Res 90, 744&#150;751 (2021).
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1038/s41390-021-01588-2</FONT></FONT></FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eleanor Pearson,
Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 9066 4071; <U>eleanor.pearson@sodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g912008dsp5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912008dsp5.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M.7+(TO&^IWFE:''<6,QAE,ZJ6"@\8/K]*V.\=X)U*\U70FN+V8RR^<R[BH'
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MU+[:UD8&*!2%R<X[_P"?2@#L/&KM)X&TIWSO9XBV?7RVH TOAW_R*X_Z[/\
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+ %N@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
